Apixaban Placebo

DRUG3 trials

Sponsors

Bristol-Myers Squibb, Janssen Research & Development, LLC

Conditions

Atrial FibrillationPulmonary EmbolismVTE Prophylaxis With Anticoagulation After Total Knee Replacement SurgeryVenous Thrombosis

Phase 2

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

CompletedNCT00097357

Bristol-Myers SquibbPulmonary Embolism, Venous Thrombosis

Start: 2004-10-31End: 2005-12-31Updated: 2010-03-02

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

CompletedNCT03251482

Janssen Research & Development, LLCVTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Start: 2017-11-13End: 2018-11-05Updated: 2019-11-25

Phase 3

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Active, not recruitingNCT05757869

Janssen Research & Development, LLCAtrial Fibrillation

Start: 2023-04-11End: 2026-10-31Updated: 2026-03-13

Related Papers

Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.

2024-08-2916 citations